Floatz logo

Mitapivat

Nephropathy

Agios Pharmaceuticals, Inc.Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Nephropathy cohort.

Asset / SponsorPhaseRating
Folic Acid
Fuling Central Hospital of Chongqing City
Phase 2/3BB
Spironolactone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
VALSARTAN
Columbia University
Phase 4BB
Nifedipine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB
Lisinopril
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB

View all 18 →

Same molecule, other indications

Mitapivat is also rated in:

sickle cell diseaseDormant
BB
Indicative ·
65 / 100
View asset →
alpha thalassemia spectrumDormant
B
Indicative ·
60 / 100
View asset →
beta-thalassemia majorDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →